ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion.

In the QUASAR trial, the efficacy and safety of Eylea HD were compared to Eylea in treatment-naïve patients with macular edema secondary to retinal vein occlusion including central retinal vein ...

Frosted branch angiitis is a rare condition that makes the blood vessels that supply the retina look like the frosted ...

The dilemma still holds regarding treatment of the very ischemic central retinal vein occlusion subgroup with ME with profound visual loss. Combination therapy of anti-VEGF agents and a steroid ...

Injection 8 mg to treat patients with macular edema following retinal vein occlusion (RVO). The intended patient population includes those with central, branch and hemiretinal vein occlusions.

All currently FDA-approved anti-VEGF therapies for retinal vein occlusion require monthly dosing. The company said these data will be submitted to regulatory authorities around the world ...

D in patients with macular edema secondary to retinal vein occlusion (RVO), including those with central retinal vein occlusion, branch retinal vein occlusion, or hemiretinal vein occlusion.

Pharmaceuticals announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD Injection 8 mg for the treatment of patients with macular edema following retinal vein ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD ...